Maxim's backloaded 2004

By BC Staff | May 17, 2004 | 7:00 AM GMT

Maxim Pharmaceuticals Inc. reported last week that its Ceplene histamine dihydrochloride plus IL-2 significantly improved leukemia-free survival compared to no treatment (the standard of care) in a Phase III trial